Online inquiry

IVTScrip™ mRNA-Anti-IL20, NN-8226(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12467MR)

This product GTTS-WQ12467MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL20 gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001385165.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 50604
UniProt ID Q9NYY1
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL20, NN-8226(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ12467MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ215MR IVTScrip™ mRNA-Anti-IL13, 13C5.5(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA 13C5.5
GTTS-WQ6980MR IVTScrip™ mRNA-Anti-pagA, ETI-204(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ETI-204
GTTS-WQ15471MR IVTScrip™ mRNA-Anti-MAPT, UCB-0107(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA UCB-0107
GTTS-WQ5861MR IVTScrip™ mRNA-Anti-CD40, CHIR-12,12(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA CHIR-12,12
GTTS-WQ2540MR IVTScrip™ mRNA-Anti-GCGR, AMG 477(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AMG 477
GTTS-WQ2018MR IVTScrip™ mRNA-Anti-INSR, AGT-181(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AGT-181
GTTS-WQ10542MR IVTScrip™ mRNA-Anti-PCSK9, LY-3015014(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA LY-3015014
GTTS-WQ675MR IVTScrip™ mRNA-Anti-CD276, 8H9(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA 8H9
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW